The Pap test reduces the incidence of cervical cancer and its precursors for women around the world but has limitations in sensitivity and accuracy.

Liquid-based cytology improves detection of dysplasia and cervical malignancy while producing fewer unsatisfactory or insufficient results. This supplement examines the science, development and clinical benefits of ThinPrep® - the first FDA-approved, liquid-based cytological testing method for women aged 30 and older.

Read this online supplement to learn more about the latest in developments in cervical cancer screening.